

MATERIALS LICENSE  
SUPPLEMENTARY SHEET

License number

22-02396-03

Docket or Reference number

030-02210

Amendment No. 33

St. Mary's Hospital  
Department of Radiology  
407 East Third Street  
Duluth, MN 55805

In accordance with letter dated June 25, 1985, License Number 22-02396-03 is amended as follows:

Conditions 12. and 18. are amended to read:

12. Licensed material listed in Item 6 above is authorized for use by, or under the supervision of, the following individual(s) for the materials and uses indicated:

J. J. Asta, M.D.

Groups I, II, III, IV, V and VI  
Xenon-133  
In vitro studies

Roger T. Collins, M.D.

Groups I, II, III, IV, V and VI  
Xenon-133  
In vitro studies

Mark B. Kilen, M.D.

Groups I, II, III, IV, V and VI  
Xenon-133  
In vitro studies

Charles C. Drexler, M.D.

Groups I, II, III, IV and V  
Xenon-133  
In vitro studies

Stephen L. Towle, M.D.

Groups I, II and III  
Iodine-131 for treatment of  
hyperthyroidism, cardiac  
dysfunction and thyroid  
carcinoma  
Xenon-133  
In vitro studies

Christian M. Peterson, M.D.

Groups I, II and III  
Iodine-131 for treatment of  
hyperthyroidism, cardiac  
dysfunction and thyroid  
carcinoma

J. R. Brown, M.D.

Groups I, II and III  
Xenon-133  
In vitro studies

John P. Knoedler, M.D.

Group I  
Soluble phosphorus-32 for  
treatment of leukemia,  
polycythemia vera and bone  
metastases  
In vitro studies

B509170320 B50822  
REQ3 LIC30  
22-02396-03 PDR

COPY

2  
ml 30

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License number  
22-02396-03

Docket or Reference number  
030-02210

Amendment No. 33

Raymond C. Flaas, M.D.

In vitro studies

Russel E. Reichter, M.D.

Groups I, II and III  
Iodine-131 for treatment of  
hyperthyroidism, cardiac  
dysfunction and thyroid carcinoma  
Xenon-133  
In vitro studies

18. Except as specifically provided otherwise by this license, the licensee shall possess and use licensed material described in Items 6, 7, and 8 of this license in accordance with statements, representations, and procedures contained in application received September 28, 1984; letters dated December 13, 1984, December 19, 1984 and June 25, 1985; and Model ALARA Program as contained Appendix O of Regulatory Guide 10.8, October 1980. The Nuclear Regulatory Commission's regulations shall govern the licensee's statements in applications or letters, unless the statements are more restrictive than the regulations.



For the U.S. Nuclear Regulatory Commission

Date August 22, 1985

Original Signed  
By William J. Adam, Ph.D.  
Materials Licensing Section, Region III

COPY